Skip to main content
SpringerLink
Log in

MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. A. Hagiwara, Y. Inoue, K. Wakasa, T. Haba, T. Tashiro, T. Miyamoto, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2), 533–538 (2003). doi:10.1148/radiol.2282020695

    Article  PubMed  Google Scholar 

  2. M. Puig-Domingo, E. Resmini, B. Gomez-Anson, J. Nicolau, M. Mora, E. Palomera, C. Marti, I. Halperin, S.M. Webb, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95(11), 4973–4978 (2010). doi:10.1210/jc.2010-0573

    Article  CAS  PubMed  Google Scholar 

  3. A. Heck, G. Ringstad, S.L. Fougner, O. Casar-Borota, T. Nome, J. Ramm-Pettersen, J. Bollerslev, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 77(1), 72–78 (2012). doi:10.1111/j.1365-2265.2011.04286.x

    Article  CAS  Google Scholar 

  4. I. Potorac, P. Petrossians, A.F. Daly, F. Schillo, C. Ben Slama, S. Nagi, M. Sahnoun, T. Brue, N. Girard, T. Brue, P. Chanson, G. Nasser, P. Caron, F. Bonneville, G. Raverot, V. Lapras, F. Cotton, B. Delemer, B. Higel, A. Boulin, S. Gaillard, F. Luca, B. Goichot, J.L. Dietemann, A. Beckers, J.F. Bonneville, Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr. Relat. Cancer 22(2), 169–177 (2015). doi:10.1530/ERC-14-0305

    Article  CAS  PubMed  Google Scholar 

  5. A. Heck, K.E. Emblem, O. Casar-Borota, J. Bollerslev, G. Ringstad, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine (2015). doi:10.1007/s12020-015-0766-8

    Google Scholar 

  6. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). doi:10.1210/jc.2008-2421

    Article  CAS  PubMed  Google Scholar 

  7. A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008). doi:10.1007/s12022-008-9029-z

    Article  PubMed  Google Scholar 

  8. S.L. Asa, R. Digiovanni, J. Jiang, M.L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S.J. Frank, S. Ezzat, A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67(15), 7505–7511 (2007). doi:10.1158/0008-5472.CAN-07-0219

    Article  CAS  PubMed  Google Scholar 

  9. O. Casar-Borota, A. Heck, S. Schulz, J.M. Nesland, J. Ramm-Pettersen, T. Lekva, I. Alafuzoff, J. Bollerslev, Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J. Clin. Endocrinol. Metab. 98(11), E1730–1739 (2013). doi:10.1210/jc.2013-2145

    Article  CAS  PubMed  Google Scholar 

  10. L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). doi:10.1210/jc.2014-2700

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Nydalen, P.b 4950, 0424, Oslo, Norway

    Ansgar Heck & Jens Bollerslev

  2. Faculty of Medicine, University of Oslo, Oslo, Norway

    Ansgar Heck & Jens Bollerslev

  3. The Intervention Centre, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Kyrre E. Emblem

  4. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

    Olivera Casar-Borota

  5. Department of Pathology, Oslo University Hospital, Oslo, Norway

    Olivera Casar-Borota

  6. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Geir Ringstad

Authors
  1. Ansgar Heck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyrre E. Emblem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivera Casar-Borota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Geir Ringstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jens Bollerslev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ansgar Heck.

Ethics declarations

Disclosure

AH has received speaker fees from Novartis, Ipsen, NovoNordisk, Pfizer and participated in Novartis’ nordic advisory board. KEE has intellectual property rights at NordicNeuroLab AS. JB has received an unrestricted research Grant from Novartis, Pfizer and Merck Norway AS. The other authors have nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heck, A., Emblem, K.E., Casar-Borota, O. et al. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53, 327–330 (2016). https://doi.org/10.1007/s12020-015-0816-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0816-2

Keywords

Search

Navigation